About
First Name:
Last Name:
Title and Organization:
Bio:
David A. Carmel joined the FNIH as its first Chief Growth and Innovation Officer in September 2022. He serves as a key member of the executive leadership team, leading the FNIH communications, events and fundraising divisions and helping to expand the foundation’s scale and impact.
Prior to joining the FNIH, Mr. Carmel served as Senior Vice President, Public Affairs and Communications, at eGenesis, a gene-editing company. He was responsible for all public and investor relations and led the company’s $125 million Series C financing from leading institutional investors in healthcare. Earlier, he was Vice President, Medical Affairs and Strategic Alliances, at Altara Biotherapeutics, and Co-Founder and Principal of Carmel Asset Management, an investment partnership where he was responsible for life science investments. He has also held positions in public affairs and business development at StemCyte, Pfizer, and Johnson & Johnson. He served as a White House Fellow from 2002 to 2003.
Mr. Carmel was appointed by Governor Andrew Cuomo to the New York Life Science Advisory Board. He is a Henry Crown Fellow of the Aspen Institute, a former member of the New York State Spinal Cord Injury Research Board, and a founding board member of the New York Stem Cell Foundation. He worked on the California Stem Cell Research and Cures Initiative, which provided $3 billion to fund stem cell research. He earned a bachelor’s degree, magna cum laude, from Harvard College and an MBA with a certificate in health care from the Stanford Graduate School of Business.
Fellowship Program
Class
